Nurix Therapeutics (NRIX) Stock Price, News & Analysis

Company Overview

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $19.66 to $20.61
• 50-Day Range: $19.83 to $28.14
• 52-Week Range: $7.65 to $29.56
• Volume: 2.91 million shs
• Average Volume: 912,122 shs
• Market Capitalization: $1.40 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.35
• Consensus Rating: Moderate Buy

Nurix Therapeutics Stock Analysis - MarketRank™

Nurix Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 557th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 16 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Nurix Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nurix Therapeutics are expected to grow in the coming year, from ($2.81) to ($2.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nurix Therapeutics is -6.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nurix Therapeutics is -6.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nurix Therapeutics has a P/B Ratio of 4.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.20% of the outstanding shares of Nurix Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Nurix Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Nurix Therapeutics has recently decreased by 2.60%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nurix Therapeutics does not currently pay a dividend.

Dividend Growth

Nurix Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.20% of the outstanding shares of Nurix Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Nurix Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Nurix Therapeutics has recently decreased by 2.60%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.63

News Sentiment

Nurix Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Nurix Therapeutics this week, compared to 5 articles on an average week.

Search Interest

Only 5 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $437,453.00 in company stock.

Percentage Held by Insiders

Only 7.20% of the stock of Nurix Therapeutics is held by insiders.

NRIX Stock Analysis - Frequently Asked Questions

How have NRIX shares performed this year?

Nurix Therapeutics' stock was trading at $10.32 at the beginning of the year. Since then, NRIX shares have increased by 92.2% and is now trading at $19.83.
View the best growth stocks for 2024 here.

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its quarterly earnings results on Friday, October, 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.67). The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative trailing twelve-month return on equity of 63.39% and a negative net margin of 313.65%.

When did Nurix Therapeutics IPO?

Nurix Therapeutics (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Nurix Therapeutics' major shareholders?

Top institutional shareholders of Nurix Therapeutics include Redmile Group LLC (6.04%), Wellington Management Group LLP (4.92%), State Street Corp (3.35%) and ARK Investment Management LLC (3.13%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Stefani Wolff.
View institutional ownership trends.

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V).

Company Calendar

• Last Earnings: 10/11/2024
• Today: 12/22/2024
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRIX
• CUSIP: N/A
• CIK: 1549595
• Web: www.nurixtx.com
• Phone: 415-660-5320
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $30.35
• High Stock Price Target: $41.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +53.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 17 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-143,950,000.00
• Net Margins: -313.65%
• Pretax Margin: -313.19%
• Return on Equity: -63.39%
• Return on Assets: -41.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.28
• Quick Ratio: 5.28

Sales & Book Value

• Annual Sales: $56.42 million
• Price / Sales: 24.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.13 per share
• Price / Book: 4.80

Miscellaneous

• Outstanding Shares: 70,836,000
• Free Float: 65,736,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 2.11